A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of 14C-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants

Mobocertinib (TAK-788) is a first-in-class oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that received accelerated approval for the treatment of patients with non-small cell lung cancer with EGFR exon 20 insertion mutations previously treated with platinum-based chemotherapy...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Investigational new drugs 2024-08, Vol.42 (4), p.343
Hauptverfasser:	Hanley, Michael J, Zhang, Steven, Griffin, Robert, Zhu, Sean Xiaochun, Fram, Robert J, Lin, Jianchang, Venkatakrishnan, Karthik, Gupta, Neeraj
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!